dLife network reports significant hike in web traffic

Share this article:
Multimedia diabetes network dLife said total visits to its website crossed the one-million mark for the month of November.

The milestone represents a 35% increase versus November 2008 in visits and page views for the diabetes-focused site, the network said, citing Google Analytics stats.

Commenting on the growth, Greg Zegras, dLife COO, told MM&M, “It's a culmination of improvements we've been making to the site over the last 12 months as well as a peak in awareness around [the American Diabetes Association's] American Diabetes Month.”

Zegras said the network has been investing in online tools, including recipes and a food look-up that shows detailed nutritional analyses—information important to patients and caregivers. In addition, an online community was launched last January enabling users to create profiles, share comments and post photos.

The mix has proved attractive to advertisers in the diabetes space. The site's current pharmaceutical brand lineup includes Pfizer's Lyrica, which is approved for treating diabetic nerve pain, as well as Novo Nordisk's insulin line, Lantus (Sanofi-Aventis), Glucagon and Humalog KwikPen (Eli Lilly), Byetta (Amylin/Lilly), Avandia (GlaxoSmithKline) and Actos (Takeda).

dLife, whose media outlets include the dLifeTV program, said the following companies have recently aired ads against the show: Merck for Januvia, Sanofi-Aventis for Lantus and Roche for AccuCheck. The dLifeTV program appears on CNBC.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?